BIOMAT Database Logo BIOMAT Database Logo

Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. 2003

Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Department of Clinical Pharmacy, University Medical Centre, Nijmegen, The Netherlands.

Patients receiving a lopinavir/ritonavir and saquinavir dual protease inhibitor-based antiretroviral salvage regimen were studied to evaluate the pharmacokinetics, tolerability and efficacy of the regimen. Pharmacokinetic curves were obtained for lopinavir and saquinavir. Patient records were studied for adverse events and efficacy data. The pharmacokinetics of lopinavir and saquinavir were comparable with literature data, except for the saquinavir 0-12 h area under the curve and maximum concentration. The tolerability of the regimen was good and efficacy was encouraging.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016879 Salvage Therapy A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases. Salvage Treatment,Therapy, Salvage,Salvage Therapies,Salvage Treatments,Therapies, Salvage,Treatment, Salvage,Treatments, Salvage
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug
D061466 Lopinavir An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A. A-157378.0,ABT 378,ABT-378,N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide,A 157378.0,A157378.0,ABT378
D019258 Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Invirase,Ro 31-8959,Saquinavir Mesylate,Saquinavir Monomethanesulfonate,Saquinivir,Monomethanesulfonate, Saquinavir,Ro 31 8959,Ro 318959

Related Publications

Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.
April 2008, Journal of acquired immune deficiency syndromes (1999),
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
January 2005, AIDS (London, England),
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
April 2005, AIDS (London, England),
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
October 2005, The Pediatric infectious disease journal,
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
October 2002, AIDS (London, England),
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
January 2000, The Pediatric infectious disease journal,
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
May 2007, The Journal of antimicrobial chemotherapy,
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
March 2002, AIDS (London, England),
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
November 2004, Antimicrobial agents and chemotherapy,
Charles J L la Porte, and Jan-Christian Wasmuth, and Katrin Schneider, and Jürgen K Rockstroh, and David M Burger
Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
January 2006, Clinical drug investigation,
Copied contents to your clipboard!